Grifols (GIKLY) Current Deferred Revenue (2016 - 2025)
Grifols (GIKLY) reported Current Deferred Revenue of $31.4 million for Q4 2025, down 18.3% on a YoY basis from $38.5 million in Q4 2024, and down 18.3% quarter-over-quarter from $38.5 million in Q4 2024.
Grifols (GIKLY) Current Deferred Revenue (2016 - 2025) Analysis & Trends
Grifols has reported Current Deferred Revenue for 10 years, with the latest figure at $31.4 million in Q4 2025.
- For the quarter ending Q4 2025, Current Deferred Revenue fell 18.3% year-over-year to $31.4 million; the trailing twelve-month figure through Dec 2025 stood at $31.4 million (down 18.3% YoY), and the FY2025 full-year result was $31.4 million, down 18.3% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $31.4 million, down from $38.5 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $38.5 million in Q4 2024, with the low at $28.2 million in Q4 2022.
- Historically, Current Deferred Revenue has averaged $33.4 million across 5 years, with a median of $31.4 million in 2025.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue jumped 37.93% — and 2022, when it fell 25.23%.
- Grifols' Current Deferred Revenue stood at $37.7 million in 2021, then slipped by 25.23% to $28.2 million in 2022, then gained by 10.14% to $31.1 million in 2023, then rose by 23.85% to $38.5 million in 2024, then fell by 18.3% to $31.4 million in 2025.
- The last three Current Deferred Revenue figures came in at $31.4 million (Q4 2025), $38.5 million (Q4 2024), and $31.1 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.43 Mn |
| Dec 31, 2024 | 38.47 Mn |
| Dec 31, 2023 | 31.06 Mn |
| Dec 31, 2022 | 28.20 Mn |
| Dec 31, 2021 | 37.72 Mn |
| Dec 31, 2020 | 27.34 Mn |
| Dec 31, 2019 | 10.84 Mn |
| Dec 31, 2018 | 10.17 Mn |
| Dec 31, 2017 | 5.04 Mn |
| Dec 31, 2016 | 476,158.38 |